Effect of cellular type on expression of acid beta-glucosidase: implications for gene therapy in Gaucher disease.
The effects of cellular type on the expressed activity of acid beta-glucosidase were evaluated using retroviral constructs containing the human cDNA. MFG retroviral ecotropic and amphotropic vectors containing the human acid beta-glucosidase cDNA were produced and used to infect different murine cell lines (fibroblast, neuronal and monocytic) and human cells (HL60 and cord blood CD34+), respectively. The expression of human acid beta-glucosidase was evaluated by enzyme activity assays, quantitative Western blots and immunofluorescence. All cells permanently integrated viruses and expression of enzyme protein was achieved in all cell lines, but cellular transduction efficiency differed even between different neuronal cell lines (eg N18S > PC12). In most cell lines acid beta-glucosidase activity was increased between two- and three-fold with concomitant signal increases by Western blot and immunofluorescence N18S cells had poor transduction efficiency, but high cellular expression in transduced cells. In NIH3T3 and MC3T3-E1 cells acid beta-glucosidase protein was expressed in 2-, 7- and 14-day cultures after infection and at least to passage four. The expressed acid beta-glucosidase in NIH3T3 cells was at two to three times normal activity levels, and was processed similarly to the human fibroblast enzyme. Inactive human acid beta-glucosidase was expressed in MC3T3-E1 preosteoblastic cells and this was maintained during differentiation to osteoblasts. These results indicate that gene transfer results in cell lines may not be generally extrapolated to all cells in tissues or to differentiated progeny.
Xu
Y H
YH
Children's Hospital Research Foundation, Division of Human Genetics, Cincinnati, Ohio 45229-3039, USA.
Wenstrup
R
R
Grabowski
G A
GA
D016475:3T3 Cells; D000818:Animals; D018952:Antigens, CD34 / Q000032:analysis; D001483:Base Sequence; D002460:Cell Line; D005312:Fetal Blood / Q000166:cytology; D005776:Gaucher Disease / Q000201:enzymology / Q000628:therapy*; D015870:Gene Expression; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics*; D005962:Glucosylceramidase / Q000096:biosynthesis* / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D018922:HL-60 Cells; D006801:Humans; D051379:Mice; D008969:Molecular Sequence Data; D008970:Molecular Weight; D009000:Monocytes; D009474:Neurons / Q000166:cytology; D010006:Osteoblasts; D012190:Retroviridae / Q000235:genetics
D018952:Antigens, CD34; D005962:Glucosylceramidase